biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Harvard Business Review | A PwC analysis shows that medications like Ozempic Zepbound may be catalyzing a behavioral and economic shift on par with major GLP-1 Receptor Agonists Obesity Drugs

Twice-daily exenatide (Byetta) carries the highest rates, with up to 3040% of patients affected

Contains 0.9% benzyl alcohol preservative

By 2008, however, the LPD had encountered some technical issues, delaying its official deployment until 2009

If no abnormalities are found, a repeat colonoscopy is generally recommended in 10 years for individuals at average risk

Lack of sleep also makes you hungrier, causes you to store more fat, and makes your body less sensitive to the hormone insulin, sabotaging attempts to lose weight and increasing your risk of developing type 2 diabetes or cardiovascular disease

Your healthcare provider needs to know your treatment goals and priorities